Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes
Robert I. Haddad(Georgetown University), Steven I. Sherman(The University of Texas MD Anderson Cancer Center), Lori J. Wirth(Massachusetts General Hospital), Manisha H. Shah(Pakistan Institute of Medical Sciences), Martin Schlumberger(Institut Gustave Roussy), Corina E. Dutcus(Eisai (United States)), Eric J. Sherman, Bruce Robinson(University of Michigan), Angela Teng(Eisai (United States)), Andrew G. Gianoukakis(UCLA Medical Center)
Cited by 104
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926